1. Synthesis and Evaluation of New Phenyl acrylamide Derivatives as Potent Non-nucleoside anti-HBV Agents. Gu, X., Y. Zhang, Y. Zou, X. Li, M. Guan, Q. Zhou, and J. Qiu. Bioorganic & Medicinal Chemistry, 2021. 29: 115892. PMID[33285406].
[PubMed]. HBV_01_2021.
2. Potent and Specific Inhibition of NTCP-mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-available Cyclosporine A Analogue. Liu, Y., H. Ruan, Y. Li, G. Sun, X. Liu, W. He, F. Mao, M. He, L. Yan, G. Zhong, H. Yan, W. Li, and Z. Zhang. Journal of Medicinal Chemistry, 2021. 64(1): p. 543-565. PMID[33369415].
[PubMed]. HBV_01_2021.
3. Design and Synthesis of 4'-Cyano dideoxy isonucleosides and Their Activity against HBV-1 and HIV. Onitsuk, K., K. Yamaguchi, R. Tokuda, N. Higashi-Kuwata, S. Kuwahara, H. Kumamoto, K. Maeda, K. Haraguchi, H. Mitsuya, and S. Imoto. Heterocycles, 2020. 100(10): p. 1599-1612. ISI[000602679100003].
[WOS]. HBV_01_2021.
4. Thiol-ene Enabled Preparation of S-Lipidated anti-HBV Peptides. Shepperson, O.A., A.J. Cameron, C.J. Wang, P.W.R. Harris, J.A. Taylor, and M.A. Brimble. Organic & Biomolecular Chemistry, 2021. 19(1): p. 220-232. PMID[33185215].
[PubMed]. HBV_01_2021.
Patent Citations
5. Cyclic Dinucleotides as Sting Agonists. Li, J., Z. Wang, L. Gu, and S. Xu. Patent. 2021. 2020-CN103987 2021013234: 48pp.
[Patent]. HBV_01_2021.
6. Substituted Heterocycles as Antiviral Agents. Panarese, J., S. Bartlett, D. Davis, N. Kenton, and Y.S. Or. Patent. 2021. 2020-US41532 2021007488: 71pp.
[Patent]. HBV_01_2021.